Active, not recruitingPHASE1, PHASE2NCT03033914

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Alison Moskowitz, MD, MD
Memorial Sloan Kettering Cancer Center
Intervention
doxorubicin(drug)
Enrollment
82 enrolled
Eligibility
18 years · All sexes
Timeline
2017 – 2027

Study locations (10)

Collaborators

Bristol-Myers Squibb · Barbara Ann Karmanos Cancer Institute · British Columbia Cancer Agency

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03033914 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma →

← Back to all trials